Nexell Sues Sublicensee Miltenyi In Defense Of Stem Cell Purification Patents
This article was originally published in The Gray Sheet
Executive Summary
Nexell Therapeutics' second move to defend patents covering the firm's proprietary stem cell purification technology kicked off with the recent filing of a patent suit in Delaware federal court.
You may also be interested in...
FDA Should Resolve Patent Dispute In AmCell Case, Delaware Court Rules
FDA should clarify whether an exemption in U.S. patent law protects AmCell Corp. from a patent infringement suit by Nexell Therapeutics, according to a summary judgment by the federal district court in Wilmington, Delaware.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.